Anavex Life Sciences Corp. Stock News

NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL ), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer''s disease, Parkinson''s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in the Annual Needham Virtual Neuroscience Forum in a fireside chat on Wednesday, March 16 th 2022 at 8:00 AM ET. A live audio webcast will be accessible at https://wsw.com/webcast/needham118/avxl/2274180 or through Company''s website at www.anavex.com . An archived edition of the session will be available later that day. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (NASDAQ: AVXL ) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer''s disease, Parkinson''s disease, Rett syndrome and other central nervous …

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 1, 2022, before the market opened, Anavex announced that a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoint

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated thera

In last trading session, Anavex Life Sciences Corp. (NASDAQ:AVXL) saw 1.78 million shares changing hands with its beta currently measuring 0.70. Company’s recent per share price level of $9.74 trading at -$1.0 or -9.31% at ring of the bell on the day assigns it a market valuation of $758.26M. That closing price of AVXL’s stock … Analysts Say That Anavex Life Sciences Corp. (NASDAQ:AVXL) Is Likely To Make It To $42.00 In 12 Months Read More »

An investigation for investors in Anavex Life Sciences Corp. (NASDAQ:AVXL) shares over potential securities laws violations by Anavex Life Sciences Corp. was announced. San Diego, CA -- ( SBWIRE ) -- 02/23/2022 -- Anavex Life Sciences Corp. is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL), have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Anavex Life Sciences Corp. regarding its business, its prospects and its operations were materially false and misleading at the time they were made. New York based Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Before the market opened on February 1, 2022, Anavex Life Sciences Corp. announced that a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoints.

AVXL earnings call for the period ending December 31, 2021.

AVXL earnings call for the period ending December 31, 2021.

Anavex Life Sciences Corp. (NASDAQ:AVXL) price on Wednesday, February 09, rose 5.77% above its previous days close as an upside momentum from buyers pushed the stocks value to $11.74. A look at the stocks price movement, the close in the last trading session was $11.10. The beta value (5-Year monthly) was 0.61. Turning to its Anavex Life Sciences Corp. (AVXL) Is A Possible Investment At Current Levels Read More »

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in the virtual 11 th Annual SVB Leerink Global Healthcare Conference and present on Wednesday, February 16 at 3 pm ET.

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu

NEW YORK , Feb. 9, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL ) resulting from allegations that Anavex may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Anavex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery Full story available on Benzinga.com

Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q1 2022 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Humanigen Announces Agreement With French CDMO For Fill And Finish Services For Lenzilumab Humanigen,